To produce the subject new compound usable for treating disorders associated with dysfunction in serotoninergic transmission, e.g. mental disorders or retrogressive diseases.
This N-arylpiperidine compound is represented by formula I [(m) is an integer of 1-5; (n) is 1 or 2; R is H, a straight-chain or branched chain 1-5C alkyl, etc.; E is H or methyl; Ar is a group represented by formula II (X is H or a halogen), etc.; A is a group represented by formula III (X1 to X4 are each H, a halogen, etc.)] or its physiologically permissible salt or an acid addition salt thereof, e.g. N-[1-(2,3-dihydro[1,4]benzodioxin-5-yl)piperid-4- yl]-N-[2-(idean-1-yl)ethyl]amine and its hemifumarate. The compound can be produced by condensing a compound represented by formula IV with an amine represented by formula V using carbonyldiimidazole in dichloromethane, providing a compound represented by formula VI and then reducing the resultant compound.
GOUMENT BERTRAND
MILLAN MARK
GOBERT ALAIN
AUDINOT VALERIE
Next Patent: TRICYCLIC HETROCYCLIC COMPOUND